MUMBAI: Daiichi Sankyo India Pharma Pvt. Ltd. (DSIN), an organization working in the field of innovative pharmaceutical Research & Development (R&D) in India, has shut down its India research division.
The reason behind of its shut down is cited as the company wanting to focus on increasing its R&D productivity as it narrows its framework to cancer research. The company would also transfer Daiichi Sankyo’s R&D Division including research themes selected by the Global Health Innovative Technology Fund GHIT Fund.
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second largest pharmaceutical company in Japan. The company owns the American biotechnology company Plexxikon, the German biotechnology company U3 Pharma and recently sold Ranbaxy Laboratories in India.
It is also a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
According to a statement from the company, “Daiichi Sankyo is reviewing its global R&D system with the aim of decreasing R&D operation costs and redistributing resources to the further development of its R&D pipeline.”
The research centre’s focused on small molecule drug discovery research in areas of infectious as well as autoimmune diseases also to identifying first in class molecules that target novel mechanism of action for diseases of the airway, musculoskeletal system, gastrointestinal system and central nervous systems, Reports ET.
Following its closure in India, the company would have no assets in Indian borderline.